| HOME >> BIOLOGY >> TECHNOLOGY |
Revenue from non-mechanical heart valve businesses expected to grow by over
100%, year-over-year
MINNEAPOLIS, April 3, 2008 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported preliminary revenue results for the first quarter of 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)
The Company currently expects revenue for the first quarter 2008 to be between $14.6 and $14.8 million, which would represent an increase of approximately 36% over first quarter 2007 revenue of $10.8 million. Revenues from products and services other than the Company's mechanical heart valves are expected to exceed $5.0 million, a quarterly record, and represent approximately 34% of total revenue during the first quarter of 2008 compared with 23% in the first quarter of 2007 and 33% in the fourth quarter of 2007. The Company expects to release its first quarter results on May 5, 2008.
"The first quarter was a strong start to 2008, with higher revenue across all our business segments," said Michael Dale, Chairman, President and CEO of ATS Medical. "ATS CryoMaze(TM) surgical ablation revenue was especially strong, up approximately 160% over the prior year's first quarter. We were also pleased with the continued increase in revenue from mechanical heart valves internationally, up approximately 32% from last year."
"While we continue to seek FDA approval of our ATS 3f(R) Aortic
Bioprosthesis tissue valve, we have maintained our focus on growing revenue
in each of our other businesses, and witnessed sequen
'/>"/>
| SOURCE ATS Medical, Inc. Copyright©2008 PR Newswire. All rights reserved |